drugset / Trial / NCT02365506
Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of the study is to evaluate the effect of oral eleclazine (formerly GS-6615) on corrected QT (QTc) interval in participants with long QT2 syndrome.
Timeline
- Start
- 2015-07-20
- Primary completion
- 2016-05-13
- Completion
- 2016-06-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eleclazine | Small molecule | 24 mg | Oral |
| Subject | Eleclazine | Small molecule | 48 mg | Oral |